Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday. They currently have a $12.00 price target on the biotechnology company’s stock, up from their prior price target of $10.00. HC Wainwright’s price target indicates a potential upside of 104.08% from the company’s previous close.
Several other equities analysts have also issued reports on AUPH. Canaccord Genuity set a $11.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 24th. Leerink Swann upped their target price on Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Zacks Investment Research raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a report on Tuesday, August 15th. Vetr lowered Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 target price for the company. in a report on Wednesday, September 6th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $14.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, October 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $10.48.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 5.88 on Monday. Aurinia Pharmaceuticals has a 52 week low of $2.02 and a 52 week high of $10.54. The company’s market capitalization is $490.89 million. The stock’s 50 day moving average price is $6.29 and its 200 day moving average price is $6.46.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.10. The company had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. Analysts anticipate that Aurinia Pharmaceuticals will post ($1.01) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.com-unik.info/2017/11/01/aurinia-pharmaceuticals-inc-auph-stock-rating-reaffirmed-by-hc-wainwright.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in AUPH. Royal Bank of Canada grew its holdings in Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 1,341 shares during the period. Jane Street Group LLC bought a new position in Aurinia Pharmaceuticals during the first quarter valued at $155,000. Cutler Capital Management LLC bought a new position in Aurinia Pharmaceuticals during the second quarter valued at $184,000. Investment Centers of America Inc. bought a new position in Aurinia Pharmaceuticals during the second quarter valued at $184,000. Finally, Kazazian Asset Management LLC grew its holdings in Aurinia Pharmaceuticals by 47.3% during the second quarter. Kazazian Asset Management LLC now owns 66,304 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 21,304 shares during the period. 27.73% of the stock is owned by institutional investors and hedge funds.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
What are top analysts saying about Aurinia Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aurinia Pharmaceuticals Inc and related companies.